Observational studyJournal of nephrology2021
Kidney injury molecule-1: potential biomarker of acute kidney injury and disease severity in patients with COVID-19.
Observational study in Journal of nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- The efficacy of novel biomarkers for the early detection and management of acute kidney injury: A systematic review.PloS one · 2025Pooled it
- Kidney injury molecule 1 in the early detection of acute kidney injury-a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Comparative accuracy of biomarkers for the prediction of hospital-acquired acute kidney injury: a systematic review and meta-analysis.Critical care (London, England) · 2022Pooled it
- Levels of circulating kidney injury markers and IL-10 identify non-critically ill patients with COVID-19 at risk of death.JCI insight · 2026Trial
- Targeted and untargeted cross-sectional study for sex-specific identification of plasma biomarkers of COVID-19 severity.Analytical and bioanalytical chemistry · 2026Article
- Can Biomarkers Predict Kidney Function Recovery and Mortality in Patients with Critical COVID-19 and Acute Kidney Injury?Diagnostics (Basel, Switzerland) · 2025Article
- An early HMGB1 rise 12 hours before creatinine predicts acute kidney injury and multiple organ failure in a smoke inhalation and burn swine model.Frontiers in immunology · 2024Article
- Acute Kidney Injury in Hospitalized Patients with COVID-19: Risk Factors and Serum Biomarkers.Biomedicines · 2023Article
- Treatment with quercetin inhibits SARS-CoV-2 N protein-induced acute kidney injury by blocking Smad3-dependent G1 cell-cycle arrest.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Urinary N-Terminal Pro-Brain Natriuretic Peptide Predicts Acute Kidney Injury and Severe Disease in COVID-19.Kidney & blood pressure research · 2023Observational
- The role of kidney injury biomarkers in COVID-19.Renal failure · 2022Review
- SARS-CoV-2 Infection and Candidate Biomarkers.The Eurasian journal of medicine · 2022Article
- Subclinical Acute Kidney Injury in COVID-19: Possible Mechanisms and Future Perspectives.International journal of molecular sciences · 2022Review
- Acute Kidney Injury in COVID-19 Patients: Pathogenesis, Clinical Characteristics, Therapy, and Mortality.Diseases (Basel, Switzerland) · 2022Review
- COVID-19 and Acute Kidney Injury.Critical care clinics · 2022Review
- Urine sediment findings were milder in patients with COVID-19-associated renal injuries than in those with non-COVID-19-associated renal injuries.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- Emerging early diagnostic methods for acute kidney injury.Theranostics · 2022Review
- The Antiviral Roles of Hydrogen Sulfide by Blocking the Interaction between SARS-CoV-2 and Its Potential Cell Surface Receptors.Oxidative medicine and cellular longevity · 2021Review
- Serum Lactate Level in Early Stage Is Associated With Acute Kidney Injury in Traumatic Brain Injury Patients.Frontiers in surgery · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThe aim of the current study was to evaluate whether tubular markers kidney injury molecule-1 (KIM-1) and N-acetyl-ß-glucosaminidase (NAG) are related to acute kidney injury (AKI) and severe disease in patients with COVID-19. METHODS AND
resultsIn this prospective observational clinical trial we examined a cohort of 80 patients with proof of acute respiratory infection and divided them into a COVID-19 cohort (n = 54) and a control cohort (n = 26). KIM-1 and NAG were measured from urine samples collected in the emergency department. We assessed the development of AKI, admission to the intensive care unit (ICU) and intrahospital death as clinical endpoints. Urinary KIM-1 and NAG were not significantly different between patients with SARS-CoV-2 and those with other respiratory infections (each p = n.s.). Eight patients from the COVID-19 cohort and five of the non-COVID-19-patients suffered from acute kidney injury during their stay. Nine COVID-19 patients and two non-COVID-19 patients were admitted to the ICU. KIM-1 was significantly elevated in COVID-19 patients with, compared to those without AKI (p = 0.005), as opposed to NAG and creatinine (each p = n.s.). Furthermore, KIM-1 was significantly elevated in the patients with COVID-19 that had to be transferred to the ICU (p = 0.015), in contrast to NAG and creatinine (each p = n.s.).
conclusionAssessing KIM-1 in patients with COVID-19 might provide additional value in recognizing AKI at an early stage of disease. Further, KIM-1 might indicate higher risk for clinical deterioration as displayed by admission to the ICU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.